Seeking to build on its neuroscience product development program, Eli Lilly and Co. has put $300 million on the table to buy privately held Avid Radiopharmaceuticals Inc., a Philadelphia-based firm that develops molecular imaging compounds, including florbetapir F 18 (18F-AV-45), an investigational agent used to detect the presence of amyloid plaque in the brain – a hallmark sign of Alzheimer's disease. (BioWorld Today)